103 related articles for article (PubMed ID: 20175962)
1. Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Maiuri F; Del Basso De Caro M; Siciliano A; Peca C; Vergara P; Mariniello G; Pettinato G
Clin Neuropathol; 2010; 29(2):109-14. PubMed ID: 20175962
[TBL] [Abstract][Full Text] [Related]
2. Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas.
Strege RJ; Godt C; Stark AM; Hugo HH; Mehdorn HM
J Neurooncol; 2004; 67(1-2):29-39. PubMed ID: 15072445
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
Maiuri F; Del Basso De Caro ML; Iaconetta G; Peca C; Esposito M; de Divitiis E
Zentralbl Neurochir; 2006 Nov; 67(4):204-9. PubMed ID: 17106834
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
5. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G
J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
Schittenhelm J; Trautmann K; Tabatabai G; Hermann C; Meyermann R; Beschorner R
Mod Pathol; 2009 Dec; 22(12):1600-11. PubMed ID: 19767728
[TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Chan AS; Leung SY; Wong MP; Yuen ST; Cheung N; Fan YW; Chung LP
Am J Surg Pathol; 1998 Jul; 22(7):816-26. PubMed ID: 9669344
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclo-oxygenase-2 in ependymal tumors.
Roma AA; Prayson RA
Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
Majumdar K; Radotra BD; Vasishta RK; Pathak A
Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
[TBL] [Abstract][Full Text] [Related]
11. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.
Sminia P; Stoter TR; van der Valk P; Elkhuizen PH; Tadema TM; Kuipers GK; Vandertop WP; Lafleur MV; Slotman BJ
J Cancer Res Clin Oncol; 2005 Oct; 131(10):653-61. PubMed ID: 16133570
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
15. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.
Waha A; Baumann A; Wolf HK; Fimmers R; Neumann J; Kindermann D; Astrahantseff K; Blümcke I; von Deimling A; Schlegel U
J Neurosurg; 1996 Oct; 85(4):634-41. PubMed ID: 8814167
[TBL] [Abstract][Full Text] [Related]
16. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
17. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article.
Jiang J; Wang S; Chen Y; Wang C; Qu C; Liu Y
Medicine (Baltimore); 2018 Sep; 97(39):e12458. PubMed ID: 30278527
[TBL] [Abstract][Full Text] [Related]
19. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
20. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
